Inactive Instrument

News Cantabio Pharmaceuticals Inc. Other OTC

Equities

CTBO

US13808X2036

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson's Disease	18/08/23	AQ
Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate Researches the Therapeutic targeting of the DJ 1 Protein to Treat Immune Associated Diseases	21/10/19	CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO from CTBOD	17/07/19	CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO.D from CTBO	20/06/19	CI
Cantabio Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	17/06/19	CI
Cantabio Pharmaceuticals Inc. Announces Expiration of Employment Agreement with Simon Peace as Chief Financial Officer	21/03/19	CI
Cantabio Pharmaceuticals Inc. Announces Resignation of Simon Peace from the Board	14/12/18	CI
Cantabio Pharmaceuticals Inc. Appoints Max Zhu as a Director	15/10/18	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP	04/06/18	CI
Cantabio Pharmaceuticals Inc. to Present Positive in Vivo Efficacy Data in A Mice Model of Parkinson’S Disease from Its Dj-1 Protein Targeting Therapeutic Program At the Neuro4d Conference in Mainz, Germany	09/05/18	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP	13/02/18	CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.3 million in funding from Yorkville Advisors Global LP	19/11/17	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Yorkville Advisors Global LP	02/05/17	CI
Cantabio Pharmaceuticals Inc. to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimer's Disease At the 13th International Conference on Alzheimer's and Parkinson's Disease	14/02/17	CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Yorkville Advisors Global LP	24/01/17	CI
Cantabio Pharmaceuticals Inc. Enters into a Licensing Agreement with Cambridge Enterprise Limited	06/09/16	CI
Cantabio Pharmaceuticals, Inc. to Present Results from its DJ-1 Protein Targeting Therapeutic Programs	18/08/16	CI
Cantabio Pharmaceuticals, Inc. and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein	11/07/16	CI
Cantabio Pharmaceuticals Inc. Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with Novalix	12/04/16	CI
Gardedam Therapeutics, Inc. acquired Cantabio Pharmaceuticals Inc. in a reverse merger transaction.	18/12/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cantabio Pharmaceuticals Inc. Other OTC

Equities

CTBO

US13808X2036

Summary

Filters